• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

rebiotix

Ferring Pharma acquires Rebiotix and its microbiome therapy platform

April 5, 2018 By Sarah Faulkner

Rebiotix

Ferring Pharmaceuticals inked a deal to acquire Rebiotix and its platform of living drugs for an undisclosed amount, the companies announced today. The Roseville, Minn.-based company is developing a microbiome-based therapy to prevent recurrent Clostridium difficile infection. Its Microbiota Restoration Therapy, which is delivered via enema or a lyophilized, non-frozen oral capsule, is designed to supply a […]

Filed Under: Drug-Device Combinations, Featured, Mergers & Acquisitions, Pharmaceuticals Tagged With: ferringpharmaceuticals, rebiotix

Rebiotix develops tool to measure rehabilitation of microbiome

February 12, 2018 By Sarah Faulkner

Rebiotix

Rebiotix today unveiled its Microbiome Health Index – a tool it created to establish a standard metric that can be used to quantify how effective a microbiome-based therapy is at rehabilitating the human microbiome. The index, which was developed in partnership with data analytics firm BioRankings, combines four bacterial classes into a unidimensional expression of […]

Filed Under: Big Data, Clinical Trials, Discovery, Featured, Pharmaceuticals Tagged With: rebiotix

Rebiotix expands Phase I trial of microbiota product after initial study success

November 29, 2017 By Fink Densford

Rebiotix

Rebiotix said today it is expanding the Phase 1 study of its investigative RBX7455 drug designed to prevent recurrent Clostridium difficile infections after initial success in its two introductory cohorts in the trial. The Roseville, Minn.-based company’s RBX7455 is a lyophilized, non-frozen oral capsule formation of its Microbiota Resoration Therapy which it says is designed to “rehabilitate […]

Filed Under: Clinical Trials, Featured, Pharmaceuticals Tagged With: rebiotix

Ocular continues personnel shakeup with new CMO | Personnel Moves – Sept. 13, 2017

September 14, 2017 By Sarah Faulkner

Ocular Therapeutix

After Ocular Therapeutix‘s (NSDQ:OCUL) founder & CEO, Amar Swahney, stepped down earlier this year, pharma executive Antony Mattessich stepped in to assume the corner office. He signaled some major changes to the company’s business strategy in a call with analysts last month, including an attempt to ‘aggressively seek new partnerships’ and ‘enhance [the company’s] credibility’. As […]

Filed Under: Drug-Device Combinations, Featured, Personnel, Pharmaceuticals, Wall Street Beat Tagged With: Aeterna Zentaris, Bayer AG, Biogen Idec, Eyevensys, lyndra, Mylan, Ocular Therapeutix, Proteus Digital Health, rebiotix, Teva

Rebiotix raises $8.5m for microbiome therapy

September 6, 2017 By Sarah Faulkner

Rebiotix

Rebiotix has raised $8.5 million in a $10 million offering, according to a regulatory document that the company filed yesterday with the SEC. The offering, which consists of debt and convertible promissory notes, has garnered participation from 29 investors thus far, the company reported. Rebiotix said it is accepting minimum investments of $25,000 and that […]

Filed Under: Featured, Funding Roundup, Pharmaceuticals Tagged With: rebiotix

Rebiotix launches late-stage superbug trial for microbiome-based drug

August 8, 2017 By Sarah Faulkner

Rebiotix

Rebiotix isn’t a traditional drugmaker. Its products are alive. The 32-person company, based in Roseville, Minn., is developing a microbiome-based therapy to prevent recurrent Clostridium difficile infection. Its Microbiota Restoration Therapy, which is delivered via enema or a lyophilized, non-frozen oral capsule, is designed to supply a patient’s intestinal tract with an array of healthy, human-derived microbes. […]

Filed Under: Clinical Trials, Featured, Hospital Care, Pharmaceuticals, Regulatory/Compliance Tagged With: rebiotix

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS